The occurrence of the Trump administration against pharmaceutical advertisements is a welcome step in reducing the influence of Big Pharma on conversations between patients and their doctors.
Americans are among the few people in the world who have been bombed with advertisements for medicines that most of us do not need-New Zealand is the only other country that makes direct-to-consumer drug advertising possible. This policy has given pharmaceutical companies a significant influence on consumer behavior when it comes to health.
The executive order signed by President Donald Trump last week is an attempt to force these companies to be more transparent about the side effects of their products – and hopefully to draw the necessary attention to the ever -treacherous ways in which industry reaches consumers. But the order is meaningless without heavy enforcement. Let us hope that the Food and Drug Administration, which is already struggling with the weight of mass fired, have the resources and leadership to continue.
The president does not ask for a total prohibition, but instead restores the regulations from the nineties that companies obliged to spelling the often comically long list of possible side effects of their products. Those guidelines were detached in 1997, when the FDA said that companies could, instead, summarize the most important side effects and lead the public to other sources for more information.
Pharma feeds media
Pharma quickly benefited from the mitigating rules. The expenditure on advertisements were bleached and reached up to around $ 10.1 billion in 2024, according to Mediaradar. That is the money from the branch made of vital importance for the media ecosystem: television networks absorb approximately half of the total advertising budget from Direct-to-Consumer (DTC).
Nevertheless, countless studies have emphasized how these advertisements can influence – too often, not in a good way – that choose medicines, especially older Americans. The effect was so remarkably early in the regulation shift that in 2015 the American Medical Association called for a ban on DTC advertising for pharmaceutical and medical devices.
Research shows that the medicines that are pushed often offer minimal advantage. An analysis of 2023 of advertisements with direct to consumption between 2015 and 2021 showed that two -thirds contained products that were considered a low therapeutic value, which means that they offered little improvement compared to existing (and often cheaper) medicines.
In the meantime, pharmaceutical companies spent almost $ 16 billion in that period to attract those products with a low value.
Another 2023 study showed in the same way that companies spend the most on products that offered the least benefits, where researchers were the hypothesis that these expenditures helped patients ask for products that would have prescribed less their doctors. Given this, it is worth asking if these advertisements should be needed to not only record extensive information about their side effects, but also an explanation about their relative value compared to other products.
When announcing the strategy change, the FDA gave a nod to the investigation.
“For far too long, these advertisements have distorted the doctor-patient relationship and have created an artificial demand for medicines, regardless of their clinical suitability,” said FDA commissioner Marty Makary in a post on social media. Makary added that the agency sends enforcement action letters to around 100 pharmaceutical companies, and that thousands more will be put alert that the agency keeps a close eye on their practices.
He said that online pharmacies, “who have increasingly promoted drugs without reporting side effects”, have also been informed. That seems to be part of a wider desk plan to close the “digital meshes” in DTC advertisement regulations -and there are many gaps in the rules that can be used.
Omnipresent exposure
Our exposure to drug options is far beyond the commercial breaks during the evening news and the radio spots during an Uber ride.
Now we hear about products in our Instagram feed when celebrities we follow, endorse them; from telehealth companies or online pharmacies that push treatments to improve sexual function; And by influencers who offer testimonials – sometimes paid, sometimes not, a distinction that is often unclear to the casual scroller – about products that they claim to improve their health. Of course, many of us can sing together with the Jingle of Novo Nordisk, “Oh, oh, ozempic”, but I suspect that most of us first became familiar with the medicine, not by the advertisement, but by noticing the dramatic body transformation of a celebrity or the journey of a stranger.
That everything argues will be a heavy lift.
Last week’s action by the administration is in the right direction, but the details of what it entails remain unclear. For example, Makary has not yet made one of the letters sent during this early action, making it difficult to assess what the actions of the FDA actually mean for companies – or how easily any changes can be enforced. Moreover, the office that is responsible for drug advertising supervision in the spring connections at the agency, and then important leaders resigned, which left the question of whether it was even the capacity to stay informed of, let alone, bad actors.
And of course Big Pharma lawyers have certainly revised the first amendment in preparation for legal fights on any limitations.
Yet some movement in this area is welcome – a push further to a ban would be even more welcome. In the meantime, attention to the subject should serve as a timely memory for the consumer that their doctor is the best information source about what they do and does not have to improve their health.
Lisa Jarvis is a Bloomberg -Opinion -Columnist for Biotech, Healthcare and the Pharmaceutical Industry. © 2025 Bloomberg. Distributed by Tribune Content Agency.
#Jarvis #Trumps #action #drug #advertisements #long #late